CRISPR THERAPEUTICS AG
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | — | $-29.1M | $156.0M |
| FY2016 | — | $232.8M | $315.5M |
| FY2017 | — | $187.8M | $239.8M |
| FY2018 | — | $392.2M | $456.6M |
| FY2019 | — | $939.4M | $943.8M |
| FY2020 | — | $1.66B | $1.17B |
| FY2021 | — | $2.40B | $923.0M |
| FY2022 | — | $1.88B | $211.9M |
| FY2023 | — | $1.88B | $389.5M |
| FY2024 | — | $1.93B | $298.3M |